UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 22, 2023
CELL MEDX CORP.
(Exact name of registrant as specified in its charter)
NV | 000-54500 | 38-3939625 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
820 - 1130 Pender Street, West Vancouver, British Columbia | | V6E 4A4 |
(Address of principal executive offices) | | (Zip Code) |
| | |
Registrant’s telephone number, including area code: | (844) 238-2692 |
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
ITEM 8.01OTHER EVENTS.
On November 22, 2023, the British Columbia Securities Commission (the “BCSC”) issued an order (the “Revocation Order”) revoking the Cease Trade Order previously issued by the BCSC on October 11, 2022, in respect of Cell MedX Corp. (the “Company”). The CTO was previously issued by the BCSC for the Company failing to file audited financial statements and related management’s discussion and analysis and an annual information form within the prescribed time under applicable Canadian securities laws (the “Canadian Filings”). The Canadian Filings have now been made and the Company is currently up to date with its continuous disclosure obligations under applicable Canadian securities laws.
Attached as Exhibit 99.1 is a copy of the Company’s news release with respect to the Revocation Order.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
The following exhibits are provided with this Current Report:
Exhibit Number | Description of Exhibit |
99.1 | News Release dated November 27, 2023. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELL MEDX CORP. |
| |
Date: November 27, 2023 | |
| |
| By: /s/ Dwayne Yaretz |
| Dwayne Yaretz, |
| Chief Executive Officer |
3
